Metformin’s most frequent side effects hit the gut: nausea, diarrhea, bloating, and abdominal discomfort affect a substantial share of people who take the drug, and these symptoms are the main reason some people stop using it or struggle to increase their dose.1PubMed Central. Metformin-Associated Gastrointestinal Intolerance: A Narrative Review of Mechanisms and Clinical Management Beyond the stomach trouble, metformin carries a handful of less obvious effects that matter more the longer you take it, including vitamin B12 depletion, magnesium shifts, and a rare but dangerous complication involving lactic acid buildup. How these side effects play out depends heavily on dose, kidney function, and what else is going on in your body.
Gut Trouble Is the Most Common Complaint
Digestive symptoms are by far the side effect people notice first. A systematic review and meta-analysis of observational studies found diarrhea in about 7% of metformin users, bloating in about 6%, abdominal pain in about 5%, and vomiting in roughly 2%.2PubMed Central. Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: a systematic review and meta-analysis with meta-regression of observational studies Those numbers represent ongoing complaints; the share of people who experience at least some digestive upset early on, before their body adjusts, is higher. One older review puts digestive disorders at around 30% when broadly defined.3Diabetes & Metabolism. Metformin and digestive disorders
No one has a definitive explanation for why metformin upsets the gut. Proposed mechanisms include stimulation of serotonin release in the intestines, altered bile-salt absorption, and changes in how the colon handles glucose. None of these fully accounts for the range and severity of symptoms people report.4Diabetes & Metabolism. Metformin and digestive disorders What clinicians do know is that symptoms vary enormously between individuals, which suggests that personal factors like gut bacteria composition and genetics play a role.5PubMed Central. Metformin-Associated Gastrointestinal Intolerance: A Narrative Review of Mechanisms and Clinical Management
Does Extended-Release Metformin Help?
Doctors often switch patients to extended-release (XR) metformin when the standard immediate-release (IR) version causes persistent gut problems. The logic is straightforward: a slower release should mean less drug hitting the intestines at once. And some trials do support this. One study found that side effects like diarrhea, dyspepsia, and flatulence occurred in about 40% of people on IR metformin but less than half that rate on an equivalent XR dose.6PubMed. Dose Comparison And Side Effect Profile Of Metformin Extended Release Versus Metformin Immediate Release A separate meta-analysis found that a delayed-release formulation designed to deliver metformin to the lower gut cut overall GI side effects by more than half compared to IR.7PubMed Central. Efficacy and Side Effect Profile of Different Formulations of Metformin: A Systematic Review and Meta-Analysis
The evidence is muddier than those individual studies suggest, though. A systematic review comparing XR to IR across multiple trials found no statistically significant difference in GI side effects, diarrhea, nausea, vomiting, or abdominal pain when pooling the data.8PubMed Central. Long-Acting Metformin Vs. Metformin Immediate Release in Patients With Type 2 Diabetes: A Systematic Review The practical takeaway is that switching to XR is worth trying if you are struggling with gut symptoms, and some people do get meaningful relief, but it is not a guaranteed fix. Starting at a low dose and increasing slowly remains one of the most reliable strategies for managing the transition.
Vitamin B12 Depletion Over Time
This is the side effect that sneaks up on people. Metformin interferes with vitamin B12 absorption in the gut, and the longer you take it, the bigger the deficit can grow. A large study using the All of Us Research Program database found that long-term users were roughly 67% more likely to be B12-deficient than non-users, and about 38% more likely than people who had used metformin for a shorter period.9PubMed. Associations between long-term metformin use, the risk of vitamin B12 deficiency, and neuropathy: An All of Us research Program study Multiple meta-analyses have confirmed the link, with both longer duration and higher doses increasing the risk.10PubMed Central. Long-term metformin therapy and vitamin B12 deficiency: An association to bear in mind
B12 deficiency is not just a lab abnormality. It can cause nerve damage that mimics or worsens diabetic neuropathy, which creates a clinical headache: the numbness and tingling in your feet may be from diabetes itself, or from low B12 caused by the drug treating the diabetes, or both. Research has found that metformin-treated patients tend to have more severe peripheral neuropathy, and the cumulative dose of metformin correlates with the degree of nerve damage.11Diabetes Care. Association of Metformin, Elevated Homocysteine, and Methylmalonic Acid Levels and Clinically Worsened Diabetic Peripheral Neuropathy Periodic B12 testing, particularly after a few years on metformin, is a reasonable precaution. Supplementation is cheap and effective if a deficiency is caught early.
Magnesium and the Gut Microbiome
B12 gets the most attention, but metformin also appears to affect magnesium levels. Low magnesium has been reported in metformin users, potentially because the drug suppresses a magnesium-transporting channel in the kidneys and intestines with long-term use.12PubMed Central. Hypomagnesemia With Metformin Use in Diabetes Mellitus: A Case and Narrative Review Lab studies show a nuanced picture: short-term metformin exposure actually increases the activity of this channel, while long-term exposure decreases its expression, creating an inverse relationship between metformin duration and circulating magnesium.13PubMed. Metformin regulates TRPM6, a potential explanation for magnesium imbalance in type 2 diabetes patients Since magnesium deficiency can contribute to muscle cramps, fatigue, and heart rhythm issues, this is worth monitoring in long-term users, though the clinical significance is still being studied.
Metformin also reshapes the bacterial community in your gut. A randomized trial showed that metformin altered gut microbiome composition within six months, increasing levels of certain short-chain fatty acids like butyrate and acetate, which are generally considered beneficial for metabolism and gut health.14PubMed Central. Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial Animal research has confirmed a consistent pattern: metformin boosts populations of beneficial bacteria like Lactobacillus while promoting production of fatty acids tied to lower insulin resistance and reduced liver inflammation.15PubMed Central. Effects of metformin on gut microbiota and short-/medium-chain fatty acids in high-fat diet rats Some researchers believe these microbiome changes account for a portion of metformin’s glucose-lowering power, and they may also explain why the drug upsets so many stomachs during the adjustment period.
Lactic Acidosis Is Rare but Dangerous
Lactic acidosis is the side effect that generates the most fear, and it is the reason metformin packaging carries a black-box warning. The drug works partly by suppressing glucose production in the liver through a mechanism that also affects how the body processes lactate. At normal doses and in healthy kidneys, this is not a problem. But when metformin accumulates to high concentrations in the blood, typically because the kidneys are not clearing it properly, lactate can build up to dangerous levels.16PubMed. Metformin-associated lactic acidosis: Current perspectives on causes and risk
In practice, this is extremely uncommon. The reported rate is fewer than 10 cases per 100,000 patient-years of use.17PubMed. Metformin-associated lactic acidosis: Current perspectives on causes and risk Nearly all cases involve a “second hit” on top of the metformin: kidney failure, severe infection, shock, cirrhosis, or something else that already compromises the body’s ability to clear lactate. Clinicians looking at an unusually high anion gap in a diabetic patient, particularly one with deteriorating kidney function, should consider metformin as a contributing factor.18PubMed Central. Metformin-induced lactic acidosis with emphasis on the anion gap For the average person taking metformin with reasonably healthy kidneys, the risk is vanishingly small.
Kidney Function Determines Safety Boundaries
Because the kidneys are responsible for clearing metformin from the body, kidney function is the single most important variable in determining whether the drug is safe for you. Guidelines are fairly specific about the cutoffs. Metformin can be used without restriction when kidney filtration rate (eGFR) is at or above 45. Between 30 and 44, the drug should not be newly started, but if someone is already on it, a reduced dose of no more than 1,000 mg daily is recommended. Below 30, metformin is contraindicated.19PubMed Central. Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
A systematic review of 13 retrospective studies confirmed the logic behind these thresholds. Metformin was associated with reduced overall mortality in patients with an eGFR of 45 or higher, with no increased risk of acidosis. Below 30, the picture flipped: the potential for acidosis increased, and the mortality benefit disappeared.20PubMed. Safety and effectiveness of metformin in patients with reduced renal function: A systematic review The gray zone between 30 and 45 remains an area where the evidence is thin and clinical judgment matters most. For anyone on metformin long term, periodic kidney function checks are standard practice.
Alcohol and Contrast Dye
Two specific interactions deserve attention because they can tilt the risk of lactic acidosis from theoretical to real. The first is heavy alcohol consumption. When you metabolize alcohol, it shifts the chemistry inside liver cells in a way that favors lactate production over glucose production. Metformin independently inhibits glucose production through a similar redox-dependent pathway, so the two together can amplify each other’s effects on lactate.21PubMed Central. Metformin-associated Lactic Acidosis Induced by Excessive Alcohol Consumption Moderate social drinking is generally considered acceptable, but binge drinking or chronic heavy use creates a meaningful risk of triggering an acidosis episode.
The second interaction involves iodine-based contrast dyes used during CT scans and certain medical imaging procedures. These contrast agents can temporarily impair kidney function, which would slow metformin clearance and allow the drug to accumulate. The standard protocol is to stop metformin on the day of the imaging procedure and keep it paused for 48 hours afterward. If kidney function tests come back normal at that point, metformin can be restarted.22PubMed. Metformin and contrast media: where is the conflict? Stopping metformin before the procedure is not considered necessary if kidney function is normal beforehand.23PubMed Central. Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
Metformin and Exercise Performance
This one surprises a lot of people: metformin may blunt some of the fitness gains you get from aerobic exercise. A double-blinded trial in older adults found that participants randomized to metformin during 12 weeks of aerobic exercise training did not improve their whole-body insulin sensitivity or cardiorespiratory fitness as much as the placebo group. Metformin appeared to block the exercise-induced increase in skeletal muscle mitochondrial respiration, and this mitochondrial effect correlated with the diminished insulin sensitivity gains.24PubMed Central. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults
A separate prospective study of men and women with elevated blood sugar found a similar pattern: metformin users saw about half the improvement in VO2 max (a measure of cardiovascular fitness) compared to exercisers not taking the drug. Interestingly, both groups saw comparable reductions in fasting insulin resistance, so the metabolic benefits of exercise were not entirely undermined, just the fitness gains.25PubMed Central. Effects of chronic metformin treatment on training adaptations in men and women with hyperglycemia: A prospective study The response was highly variable between individuals, meaning some people on metformin adapted to exercise just fine while others saw significant blunting. This is a genuine tension point for anyone taking metformin who is also serious about building cardiovascular fitness, though the overall health calculus still strongly favors continuing to exercise.
Thyroid Hormone Levels
Metformin has a measurable effect on thyroid-stimulating hormone (TSH). A meta-analysis pooling data from five studies found that TSH levels were significantly lower after metformin treatment.26Scientific Reports. The effect of metformin therapy on serum thyrotropin and free thyroxine concentrations in patients with type 2 diabetes: a meta-analysis This matters most for people who already have thyroid conditions, particularly hypothyroidism. If you are on thyroid medication and start metformin, your TSH may shift enough to warrant dosage adjustments. The effect is not harmful for most people with normal thyroid function, but it can confuse monitoring in people with borderline or treated thyroid disease.
Metformin During Pregnancy
Metformin crosses the placenta and reaches concentrations in the fetus that range from half to nearly the same level as in the mother’s blood.27PubMed Central. Metformin from mother to unborn child – Are there unwarranted effects? That alone has kept the question of safety during pregnancy alive for decades. A register-based cohort study tracking long-term outcomes in children exposed to metformin in the womb found no increased risk of obesity, diabetes, or developmental challenges. However, metformin-exposed babies had slightly lower birth weight, averaging about 39 grams less, and a higher rate of being born small for gestational age compared to babies whose mothers used insulin alone.28BMJ Open Diabetes Research & Care. Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study Current human studies remain limited by sample size and follow-up duration, so this is an area where the reassuring signals are genuine but the picture is incomplete.29PubMed Central. Metformin from mother to unborn child – Are there unwarranted effects?
One Thing Metformin Does Not Typically Cause
People sometimes worry that metformin will drop their blood sugar dangerously low. Used on its own, metformin does not typically cause hypoglycemia, because it does not force the pancreas to release insulin the way sulfonylureas or insulin injections do. Those older drug classes increase circulating insulin regardless of where blood sugar stands, which is why they carry a real low-blood-sugar risk. Metformin works through a different pathway, primarily reducing glucose output from the liver and improving how cells respond to insulin, so it brings glucose down without pushing it into dangerous territory on its own. The risk of hypoglycemia rises when metformin is combined with insulin or sulfonylureas, but that is the other drug’s contribution, not metformin’s.
Rare but Documented Reactions
A handful of case reports describe unusual reactions to metformin that most users will never encounter. One case involved a woman who developed a skin condition called leukocytoclastic vasculitis, presenting as raised purple spots on her lower legs, shortly after starting metformin. The rash cleared after stopping the drug, then returned when she restarted it, confirming the connection.30PubMed. Rare case of metformin-induced leukocytoclastic vasculitis Acute liver inflammation triggered by metformin has also been reported, though it appears to be exceedingly rare.31PubMed Central. Metformin-Induced Acute Hepatitis
On the liver front more broadly, metformin is often a source of unnecessary anxiety. Many people with chronic liver disease, including some with cirrhosis, can use metformin safely. A pharmacokinetic study found that metformin processing in patients with chronic liver disease was similar to that in patients without liver problems, and plasma metformin and lactate levels remained well below established safety limits.32PubMed. The safety and pharmacokinetics of metformin in patients with chronic liver disease Liver disease with severe cirrhosis still requires caution, mainly because cirrhosis can impair lactate clearance, but mild to moderate liver disease is generally not a reason to avoid the drug.
Muscle Health in Animal Studies
Given metformin’s growing use beyond diabetes, including in aging research and off-label for polycystic ovary syndrome, the question of whether it affects muscle mass comes up frequently. Animal research has produced mixed but largely reassuring findings. In obese rats fed a high-fat diet, metformin appeared to protect against diet-induced muscle wasting by shifting the expression of genes involved in muscle breakdown back toward normal.33PubMed. Beneficial effects of metformin on muscle atrophy induced by obesity in rats A study in aging mice with age-related muscle loss found that five months of metformin increased the percentage of muscle mass and improved grip strength and exercise capacity in lean mice, though the benefits were weaker in obese mice with sarcopenia.34Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease. The ameliorating effects of metformin on disarrangement ongoing in gastrocnemius muscle of sarcopenic and obese sarcopenic mice In older female rats, lifelong moderate exercise combined with metformin did not eliminate the exercise benefits; metformin did not increase muscle mass on its own, but it also did not sabotage the gains from exercise, and it was associated with increased lifespan.35PubMed Central. Long-Term Moderate Exercise Combined with Metformin Treatment Induces an Hormetic Response That Prevents Strength and Muscle Mass Loss in Old Female Wistar Rats Translating any of this directly to humans is premature, but the animal data do not point to metformin as a muscle-wasting drug.